Research and Markets: Pharmaceutical Market Access in Europe: The Barriers Keep On Rising

DUBLIN--(BUSINESS WIRE)-- Research and Markets( has announced the addition of Decision Resources, Inc.'s new report "Pharmaceutical Market Access in Europe: The Barriers Keep On Rising" to their offering.

The leading European markets are among the most testing in terms of the barriers to market access that they erect. France, Italy, and Spain have complex pricing and reimbursement procedures: prices are benchmarked and strictly controlled, innovation is a key factor in determining price and reimbursement status, and launch delays can be substantial. By comparison, Germany and the United Kingdom were historically free pricing markets, characterized by relatively high prices and minimal delays in launching new drugs. However, Germany is in the process of implementing a radical overhaul of its pricing system, and the United Kingdom plans to introduce major reforms in January 2014.

Key Topics Covered:

Executive Summary

  • Strategic Considerations
  • Stakeholder Implications

Overview European Environment

  • Market Access Delays
  • European Commission Consultation on Drug Pricing and Reimbursement


  • Pharmaceutical Pricing
  • Standard Procedure for Setting Reimbursement Prices
  • Price Setting for Innovative Drugs
  • Admission to Reimbursement
  • Health Technology Assessment
  • Plans for an Overhaul of the French Regulatory System


  • Pharmaceutical Pricing
  • New Requirement for Value Dossiers
  • New Price-Setting Procedures
  • Initial Impact of the Pricing Reforms
  • Industry Reactions to the Reforms
  • Admission to Reimbursement
  • Health Technology Assessment


  • Pharmaceutical Pricing and Health Technology Assessment
  • Admission to Reimbursement
  • Initiative to Promote More-Uniform Access to Innovative Drugs Across Italy


  • Pharmaceutical Pricing
  • Admission to Reimbursement
  • Health Technology Assessment

United Kingdom

  • Pharmaceutical Pricing
  • Pricing of Branded Drugs Based on New Active Substances
  • Pricing of Branded Drugs Based on Established Active Substances
  • Patient Access Schemes
  • Flexible Pricing
  • Prospective Overhaul of the Pricing System
  • Objectives of the New System
  • Initial Industry Response to Government Proposals
  • Proposed New Pricing Procedure
  • Admission to Reimbursement
  • Health Technology Assessment

For more information visit


Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Pharmaceutical



Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.